PCSK9 inhibitors × cardiovascular events

TrialEuropean heart journal2022

Alirocumab after acute coronary syndrome in patients with a history of heart failure.

Harvey D White et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 924 people · 2022

Randomised comparison

Probably reduced cardiovascular events

−15%−22% to −7%

Bigger than 3 in 10 for cardiovascular events

As reported

HR 0.85, 95% CI 0.78–0.93

One number in the abstract

the abstract, start to end

with placebo [hazard ratio (HR): 0.85; 95% confidence interval (CI):

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.850.78–0.93
PCSK9 inhibitorsCardiovascular events

PCSK9 inhibitors × cardiovascular eventshelps?settled

unlikelylikely
1.001.00 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

15 papers cite it

2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 34922353